Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor

verfasst von: Zhanwen He, Danyang Cen, Xiangyang Luo, Dongfang Li, Pinggan Li, Liyang Liang, Zhe Meng

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Invasiveness is a major clinical feature of glioma, an aggressive brain tumor with poor prognosis. Although there is emerging evidence that some microRNAs are involved in the glioma cell invasion process, it remains necessary to find functional microRNAs and elucidate the underlying molecular mechanisms. Here, we reported that a microRNA, miR-383, was downregulated in gliomas and inversely correlated with glioma pathological grades. Downregulation of miR-383 enhanced, whereas upregulation of miR-383 inhibited, the glioma cell invasive ability. Furthermore, we found that downregulation of miR-383 activated the AKT signaling following upregulation of MMP2 expression by directly targeting insulin-like growth factor 1 receptor (IGF1R). Importantly, we demonstrated that IGF1R expression is critical for miR-383 downregulation-induced cell invasion. Taken together, these findings uncover a novel regulatory mechanism for constitutive IGF1R signaling activation in glioma cancer and may provide miR-383 as a useful diagnostic marker or therapeutic target.
Literatur
1.
2.
Zurück zum Zitat Rob Stein “Malignant Gliomas Affect About 10,000 Americans Annually”. Washington Post; (May 20, 2008). Rob Stein “Malignant Gliomas Affect About 10,000 Americans Annually”. Washington Post; (May 20, 2008).
3.
Zurück zum Zitat Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006;58:701–9.PubMedCrossRef Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006;58:701–9.PubMedCrossRef
4.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef
5.
Zurück zum Zitat Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade gliomas. J Clin Oncol. 2006;24:1273–80.PubMedCrossRef Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade gliomas. J Clin Oncol. 2006;24:1273–80.PubMedCrossRef
6.
Zurück zum Zitat See SJ, Gilbert MR. Anaplastic gliomas: diagnosis, prognosis, and management. J Clin Oncol. 2004;31:618–34. See SJ, Gilbert MR. Anaplastic gliomas: diagnosis, prognosis, and management. J Clin Oncol. 2004;31:618–34.
7.
Zurück zum Zitat Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.PubMedCrossRef Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.PubMedCrossRef
8.
Zurück zum Zitat Nakagawa M, Uramoto H, Oka S, et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 2012;13:136–42.PubMedCrossRef Nakagawa M, Uramoto H, Oka S, et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 2012;13:136–42.PubMedCrossRef
9.
Zurück zum Zitat Browne BC, Eustace AJ, Kennedy S, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat. 2012;136:717–27.PubMedCrossRef Browne BC, Eustace AJ, Kennedy S, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat. 2012;136:717–27.PubMedCrossRef
10.
Zurück zum Zitat Furukawa J, Wraight CJ, Freier SM, et al. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate. 2010;70:206–18.PubMed Furukawa J, Wraight CJ, Freier SM, et al. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate. 2010;70:206–18.PubMed
11.
Zurück zum Zitat Hirano H, Lopes MB, Laws ER Jr, et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro Oncol. 1999;1:109–19.PubMed Hirano H, Lopes MB, Laws ER Jr, et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro Oncol. 1999;1:109–19.PubMed
12.
Zurück zum Zitat Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 1996;68:183–223.PubMedCrossRef Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 1996;68:183–223.PubMedCrossRef
13.
Zurück zum Zitat Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69.PubMed Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69.PubMed
14.
Zurück zum Zitat Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene. 2003 Feb 20;22(7):974–82.PubMedCrossRef Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene. 2003 Feb 20;22(7):974–82.PubMedCrossRef
15.
Zurück zum Zitat Zhang D, Bar-Eli M, Meloche S, et al. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem. 2004;279(19):19683–90.PubMedCrossRef Zhang D, Bar-Eli M, Meloche S, et al. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem. 2004;279(19):19683–90.PubMedCrossRef
16.
Zurück zum Zitat Chen YW, Boyartchuk V, Lewis BC. Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia. 2009 Sep;11(9):835–45.PubMed Chen YW, Boyartchuk V, Lewis BC. Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia. 2009 Sep;11(9):835–45.PubMed
17.
Zurück zum Zitat Bartel DP. MicroRNAs. Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRef Bartel DP. MicroRNAs. Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRef
18.
Zurück zum Zitat William CS. MicroRNAs in cancer —from research to therapy. Biochimica et Biophysica Acta (BBA) - Reviews on. Cancer. 2010;1805:209–17. William CS. MicroRNAs in cancer —from research to therapy. Biochimica et Biophysica Acta (BBA) - Reviews on. Cancer. 2010;1805:209–17.
19.
Zurück zum Zitat Ziyan W, Shuhua Y, Xiufang W, et al. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol. 2011;28:1469–74.PubMedCrossRef Ziyan W, Shuhua Y, Xiufang W, et al. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol. 2011;28:1469–74.PubMedCrossRef
20.
Zurück zum Zitat Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.PubMedCrossRef Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.PubMedCrossRef
21.
Zurück zum Zitat Yin S, Girnita A, Strömberg T, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol. 2010;12:19–27.PubMedCrossRef Yin S, Girnita A, Strömberg T, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol. 2010;12:19–27.PubMedCrossRef
22.
Zurück zum Zitat Lian J, Tian H, Liu L, et al. Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 2010;1:e94.PubMedCrossRef Lian J, Tian H, Liu L, et al. Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 2010;1:e94.PubMedCrossRef
23.
Zurück zum Zitat Li KK, Pang JC, Lau KM, et al. MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3). Brain Pathol. 2012 Dec 11. [Epub ahead of print] Li KK, Pang JC, Lau KM, et al. MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3). Brain Pathol. 2012 Dec 11. [Epub ahead of print]
24.
Zurück zum Zitat Yin M, Lü M, Yao G, et al. Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1. Mol Endocrinol. 2012;26:1129–43.PubMedCrossRef Yin M, Lü M, Yao G, et al. Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1. Mol Endocrinol. 2012;26:1129–43.PubMedCrossRef
Metadaten
Titel
Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor
verfasst von
Zhanwen He
Danyang Cen
Xiangyang Luo
Dongfang Li
Pinggan Li
Liyang Liang
Zhe Meng
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0557-0

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.